The U.S. Food and Drug Administration (FDA) released briefing documents questioning the sufficiency of data supporting the company's treatment. The FDA reiterated that the company does not have adequate evidence to support approval, marking the third time Replimune has sought clearance for the therapy.
The FDA's concerns center on the design of Replimune's single-arm trial, in which patients who had previously been treated with a PD-1 inhibitor received the company's investigational drug RP1 in combination with Opdivo (nivolumab). The regulator argued that such a study is insufficient to evaluate the treatment's efficacy and whether the locally injected therapy produces systemic benefits.
The FDA also stated that 'there is no evidence that continued anti-PD-1 monotherapy provides any level of clinical benefit' in this context, further undermining the trial's rationale.
The briefing documents were released on Tuesday ahead of an advisory committee meeting scheduled for later that week.
Updates
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee is convening this Thursday to evaluate whether Replimune has provided sufficient data for the accelerated approval of its melanoma treatment, RP1. While the drug faced a rejection in April, recent reports indicate that the prior resistance originated from FDA career staff rather than agency leadership. This upcoming advisory panel vote is widely viewed by investors as a potential indicator of a shift in how the FDA's new leadership evaluates the risk-benefit profile of investigational therapies.
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee is meeting this Thursday to evaluate whether Replimune's RP1 treatment has sufficient data for accelerated approval. This meeting follows the drug's rejection in April, though reports suggest that prior resistance stemmed from career staff views rather than then-leadership. Investors are currently monitoring the committee's vote as a potential indicator of the new administration's approach to weighing investigational drug risks and benefits.
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee is convening this Thursday to evaluate the sufficiency of data for the accelerated approval of RP1. This meeting, which investors view as a potential shift toward greater lenience under new leadership, follows the drug's rejection in April. While the panel's upcoming vote will signal how the agency balances risks and benefits, the FDA is not officially bound by these expert recommendations.
